CSL Behring
CSL Behring, headquartered in King of Prussia, in the U.S. state of Pennsylvania, is a business unit of the Australian biopharmaceutical company CSL Limited ( Commonwealth Serum Laboratories) and specializes in the manufacture of plasma products.
The business unit has approximately 8000 CSL Behring employees worldwide in 19 countries. The largest production and research site is located in Marburg in the German state of Hesse, more in Kankakee in the U.S. state of Illinois, in Bern in the Swiss canton of Bern. In addition there are offices in 16 other countries. Main markets for the drugs from human blood plasma are the USA, Europe, Japan, Latin America and the Middle East.
Products
CSL Behring develops, manufactures and distributes biotechnology products in the fields of coagulation disorder, intensive care and immunoglobulins. In Germany CSL Behring provides patients with 21 different drugs on plasma base, a recombinant factor VIII preparation and a fibrinolytic agent.
CSL Behring GmbH ( Germany )
Today's German subsidiary was founded in 1904 as Behringwerke AG from Nobel laureate in medicine, Emil von Behring, the products include serums and vaccines against infectious diseases. From 1946 the production of plasma products is added. In 1952, Hoechst Behringwerke as a subsidiary.
The mid-nineties began Behringwerke divide; while the plasma division was spun off and merged in early 1996 with the Rhône -Poulenc subsidiary Armour for joint venture Centeon. As Hoechst and Rhône -Poulenc merged to form Aventis in 1999, was from Centeon new Aventis subsidiary Aventis Behring. Since the company no longer matched the newly defined core business of Aventis, the sale to the Australian CSL Holding was agreed and completed in the first half of 2004 in December 2003. Under the CSL Aventis Behring was immediately merged with ZLB bioplasma to ZLB Behring. End of 2006, the abbreviation ZLB was in the name of the subsidiaries replaced by CSL; since been renamed the German subsidiary as CSL Behring GmbH.
Because of the production of coagulation factor VIII and von Willebrand factor was CSL Behring in 2008 for the United States as an essential facility.
CSL Behring AG ( Switzerland )
Today's Swiss subsidiary was founded in 1949 by the Swiss Red Cross (SRC ) and the Central Laboratory Blood Transfusion Service SRC ( ZLB ) in Bern. 1951 the ZLB was allowed by the federal government to produce drugs from blood plasma and to sell.
The CSL Holding took over in 2000, the Central Laboratory Blood Transfusion Service of the Red Cross and founded as a limited company under Swiss law the ZLB bioplasma. In 2001, the CSL Holding plasma laboratories in the U.S., which also contributed the acronym ZLB as part of the company name ZLB Plasma Services.
In 2004, the CSL Holding the pharmaceutical company Aventis Behring, which was merged with ZLB bioplasma to ZLB Behring. End of 2006, the acronym ZLB was replaced in the name of the subsidiaries by CSL, since renamed the Swiss subsidiary as CSL Behring AG.